Key result
The D2.mdx mouse model exhibits more pronounced early pathology than the mdx model for Duchenne muscular dystrophy, but it is not progressive and partially resolves with age.
Why the study?
Preclinical study designs frequently underestimate caveats of the D2.mdx mouse model, whose pathology does not progress and partially resolves with age.
Answers are grounded in this paper and cite their sources.
Researchers must exercise caution when using the D2.mdx mouse model for Duchenne muscular dystrophy, as its early severe pathology is not progressive and may resolve with age, potentially confounding preclinical efficacy studies.
The C57BL/10ScSn-Dmdmdx/J (mdx) mouse model has been used by researchers for decades as a model to study pathology of and develop therapies for Duchenne muscular dystrophy. However, the model is relatively mildly affected compared to the human situation. Recently, the D2.B10-Dmdmdx/J (D2.mdx) mouse model was suggested as a more severely affected and therefore better alternative. While the pathology of this model is indeed more pronounced early in life, it is not progressive, and increasing evidence suggest that it actually partially resolves with age. As such, caution is needed when using this model. However, as preclinical experts of the TREAT-NMD advisory committee for therapeutics (TACT), we frequently encounter study designs that underestimate this caveat. We here provide context for how to best use the two models for preclinical studies at the current stage of knowledge.
No takes yet. Share an insight, caveat, or question.
Aartsma‐Rus et al. (2022) conducted a review in Duchenne muscular dystrophy. D2.B10-Dmdmdx/J (D2.mdx) mouse model vs. C57BL/10ScSn-Dmdmdx/J (mdx) mouse model was evaluated. The D2.mdx mouse model exhibits more pronounced early pathology than the mdx model for Duchenne muscular dystrophy, but it is not progressive and partially resolves with age.
Synapse has enriched 10 related papers. Consider them for comparative context: